PROPHYLAXIS AND TREATMENT OF SIDE EFFECTS OF ANTIANGIOGENIC THERAPY IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review analyzed data from the literature and personal experience of the application of anti-angiogenic therapy in metastatic colorectal cancer. There are presented practical advices on prevention and treatment of the most common side effects of anti-angiogenic therapy.

Full Text

Restricted Access

About the authors

Andrey A. Meshcheryakov

N.N. Blokhin Russian Cancer Research Center

Email: a_meshcheryakov@mail.ru
MD, PhD, Senior Researcher of the Department of the Combined Chemotherapy and Treatment of Cancer of the Research Institute of Clinical Oncology; Moscow, 115478, Russian Federation. Moscow, 115478, Russian Federation

References

  1. Van Cutsem E., Cervantes A., Adam R., Sobrero A., Van Krieken J.H., Aderka A. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 2016. doi: 10.1093/annonc/mdw235.
  2. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Naure. Med. 2003; 9(6): 669-76.
  3. Giantonio B.J., Catalano P.J., Meropol N.J., O’Dwyer P.J., Mitchel E.P., Alberts S.R. et al. Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007; 25: 1530-44.
  4. Cartwright T.H. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management. Clin. Colorect. Cancer. 2013; 12(2): 86-94.
  5. Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausova J., Macarulla T. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 2012; 28: 3499-506.
  6. Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 2008; 358(11): 1129-36.
  7. Gressett S.M., Shah S.R. Intricacies of bevacizumab-induced toxicities and their management. Ann. Pharmacother. 2009; 43: 490-501.
  8. Antiangiogenic Therapy: Tolerability and Management of Side Effects. The Angiogenesis Foundation 2009 / Eds. M.E. Lacouture, D.J. Lenihan, S.E. Quaggin. http://www.angio.org/pdf/Angio_Poster_Final_6-30.pdf
  9. Maitland M.L., Bakris G.L., Black H.R., Chen H.X., Durand J.B., Elliott W.J. et al. Initial assessment, surveillance and management of blood pressure in patient receiving vascular endothelial growth factor signaling pathway inhibitors. J. Natl. Cancer Inst. 2010; 102(9): 596-604.
  10. Copur M.S., Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin. Colorect. Cancer. 2011; 10(3): 151-6.
  11. Sundararajan S., Kumar A., Poongkunran M., Kannan A., Vogelzang N.J. Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management. Future Oncol. 2016; 10.2217/fon.16.4
  12. Ghiringhelli F., Vincent J., Beltjens F., Bengrine L., Ladoire S. Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. Invest. New Drugs. 2015; 33: 1263-6.

Statistics

Views

Abstract: 193

Cited-by

CrossRef: 1

  1. Grechukhina KS, Chebotareva NV, Krasnova TN. Nephrotoxicity of anti-angiogenesis drugs. Terapevticheskii arkhiv. 2020;92(6):93. doi: 10.26442/00403660.2020.06.000672

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2017 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies